Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Nanosonics (ASX:NAN) share price slides 12% on weak FY22 outlook

Nanosonics Ltd (ASX: NAN) share price is sinking after announcing its first-half results for FY22.

Keep up to date with the February 2022 reporting season calendar.

Nanosonics designs and manufactures infection prevention equipment for hospitals and healthcare environments.

Nanosonics share price down despite 41% top-line growth

Currently, the Nanosonics share price is down 11.12% to $4.19.

Key financial results for the half ending 31 December include:

  • Revenue of $60.6 million, up 41% year-on-year (YoY)
    • Capital revenue of $19.0 million, up 102% YoY
    • Consumables and service revenue of $41.6 million, up 23% YoY
  • Earnings before tax and interest of $3.3 million, up from $0.2 million in the prior half

Nanosonics utilises a razor (capital equipment) and blade (consumables) sales model.

It installs a capital device inside a hospital and then sells the ongoing single-use products for the equipment.

The doubling of capital equipment sales is largely a result of a weak comparable period that was severely impacted by pandemic restrictions.

CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH) also called out COVID-19 headwinds in their results.

Nanosonics also benefitted from upgrading existing customers to new products.

About 25% of its current installed base is older than seven years old, illustrating meaningful potential growth in moving customers onto newer products.

Growth in consumables was more subdued and actually fell 3% when compared against the most recent half.

Again, COVID-19 disruptions continue to impact, particularly on ultrasound volumes.

North America remained the main breadwinner, with a positive contribution from Asia.

Europe and the Middle East retraced due to pandemic impacts on sales efforts.

Nanosonics eeked a small bump in its earnings as it begins to reach scale.

Investing for the future

Research and development (R&D) increased in line with revenue. A particular focus in the new endoscope reprocessing product platform Nanosonics Coris.

Nanosonics also announced it would move to a new headquarters based in Sydney.

The facility will triple its R&D capacity with new laboratories in microbiology, chemistry and engineering.

What’s next for the Nanosonics share price?

The Nanosonics share price likely fell in response to the vague guidance about the remainder of FY22.

Sales growth will be double-digit after accounting for the $13-$16 million in lost revenue from the transition away from distributor GE.

Operating expenses for the full year are expected to be $93.0 million.

The business will continue to drive new capital sales as markets begin to reopen.

Looking beyond FY22, Japan and China will be key expansion markets in addition to growth in new and existing products.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content